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Abstract
Rheumatoid arthritis (RA) is a chronic destructive autoimmune disease characterised by periods of flare and remission.
Today’s treatment is based on continuous immunosuppression irrespective of the patient’s inflammatory status. When the
disease is in remission the therapy is withdrawn but withdrawal attempts often results in inflammatory flares, and re-start of
the therapy is commenced when the inflammation again is prominent which leads both to suffering and increased risk of
tissue destruction. An attractive alternative treatment would provide a disease-regulated therapy that offers increased anti-
inflammatory effect during flares and is inactive during periods of remission. To explore this concept we expressed the
immunoregulatory cytokine interleukin (IL)-10 gene under the control of an inflammation dependent promoter in a mouse
model of RA - collagen type II (CII) induced arthritis (CIA). Haematopoetic stem cells (HSCs) were transduced with lentiviral
particles encoding the IL-10 gene (LNT-IL-10), or a green fluorescence protein (GFP) as control gene (LNT-GFP), driven by the
inflammation-dependent IL-1/IL-6 promoter. Twelve weeks after transplantation of transduced HSCs into DBA/1 mice, CIA
was induced. We found that LNT-IL-10 mice developed a reduced severity of arthritis compared to controls. The LNT-IL-10
mice exhibited both increased mRNA expression levels of IL-10 as well as increased amount of IL-10 produced by B cells and
non-B APCs locally in the lymph nodes compared to controls. These findings were accompanied by increased mRNA
expression of the IL-10 induced suppressor of cytokine signalling 1 (SOCS1) in lymph nodes and a decrease in the serum
protein levels of IL-6. We also found a decrease in both frequency and number of B cells and serum levels of anti-CII
antibodies. Thus, inflammation-dependent IL-10 therapy suppresses experimental autoimmune arthritis and is a promising
candidate in the development of novel treatments for RA.
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic autoimmune
disease that mainly affects the joints and ultimately leads to severe
bone and cartilage destruction. The clinical course of the disease is
discontinuous and characterised by spontaneous remissions and
exacerbations. The aetiology in RA is largely unknown but for
some reason the immune system - which normally protects us
against exogenous pathogens - is dysregulated and has lost its
normal tolerance to endogenous (self-) structures and mediates an
inflammatory attack against e.g. the joints. Todays treatment is
based on continuous immunosuppression either by conventional
disease modifying anti-rheumatic drugs such as methotrexate and/
or by biological agents targeting specific proteins e.g. TNF.
Unfortunately these treatment modalities can cause side effects
such as severe infections and, in addition, attempts to withdraw
therapies in established RA often leads to flares [1]. To overcome
these hurdles, disease-regulated therapy appears ideally suited, as
it would allow intrinsic expression of the immunosuppressive
therapy only during inflammatory conditions i.e. during disease
flares but not during periods of remissions. This approach has
been used successfully in experimental autoimmune encephalo-
myelitis (EAE) where, by means of transcriptionally targeted gene
therapy, a T cell targeted IL-2 promoter controlling IL-10
production delayed onset and progression of EAE [2]. It has also
been shown that disease-regulated IL-4 expression achieved via
the IL-1/IL-6 promoter can protect against cartilage destruction
in CIA [3].
Interleukin-10 is produced by a multitude of cell types during an
immune response, where one of its main functions is to limit the
ongoing response in order to protect the host from excessive
immune mediated tissue destruction (reviewed in [4]), which is one
of the characteristics in RA. Support for a role of IL-10 in RA
comes from mouse models: in the CIA model, treatment with anti-
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IL-10 antibodies aggravates the disease, as does a complete lack of
IL-10 [5,6]. This argues for IL-10 as a possible cytokine to use for
treatment of RA. Indeed, addition of recombinant IL-10 [7],
transfer of IL-10 producing cells [8] or continuous production of
IL-10 [9,10,11], reduces the severity but not the frequency of CIA.
However, a permanent increase in IL-10 levels may not be optimal
as it may also influence defence towards invading pathogens
whereas an increase exclusively during inflammation (flares) would
be preferable and could provide a treatment alternative in CIA
and RA.
Inflammation induced IL-10 transcription in endothelial cells,
driven by an E selectin promoter, has been used by Garaulet et al.
and showed promising results in ameliorating arthritis [12]. We
sought to investigate whether IL-10 expression induced by
a promoter sensitive to pro-inflammatory cytokines IL-6 and IL-
1 in haematopoetic cells, could be a candidate for tailor-made
therapy for CIA and with a long term goal also for RA patients.
Our data show that inflammation-induced local expression of IL-
10 delays progression of CIA through decreased serum levels of
IL-6 and anti-CII antibodies. This study provides evidence that
inflammation-dependent immunosuppression is a promising tool
for the treatment of autoimmune arthritis.
Results
Arthritis is Ameliorated in LNT-IL-10 Mice
To investigate whether an inflammation-dependent increase in
IL-10 production would change disease status in the CIA mouse
model, the promoter of the human cytokine gene interleukin-6 (IL-
6) in combination with the IL-1 enhancer region [13] were used to
drive the expression of the IL-10 (LNT-IL-10) or a green
fluorescent (LNT-GFP) control gene (Figure 1A). We find that
this vector gives rise to inflammation-dependent IL-10-production
in vitro (Suppl 1A). Haematopoetic stem cells (HSCs) were
transduced with LNT-IL-10 or LNT-GFP lentiviral particles and
were thereafter injected into lethally irradiated recipient mice.
After the HSCs had re-populated the immune system, CIA was
induced (12 weeks post transplantation). The integration of the
lentiviral construct was successful (Suppl 1B) and, although almost
all mice in both groups developed arthritis, those transplanted with
the LNT-IL-10 transduced HSCs showed a significant reduction
in the severity of clinical arthritis (Figure 1B). Importantly, the
histology showed reduced synovitis, and cartilage and bone
erosivity in the LNT-IL-10 mice compared with controls
(Figure 1C). Thus, integration of the LNT-IL-10 construct
containing the IL-10 gene under the regulation of an inflamma-
tion-dependent promoter suppresses the progression of CIA.
LNT-IL-10 Treatment Increases IL-10 and SOCS1
Expression in Lymph Nodes
The reduction in arthritis in LNT-IL-10 mice suggested that IL-
10 is produced. To investigate this, mRNA expression levels of IL-
10 were analysed in draining lymph nodes where, as expected, IL-
10 mRNA levels were increased in LNT-IL-10 mice compared
with controls (Figure 2A). In addition, flow cytometric analysis of
lymph node cells from LNT-IL-10 mice at termination of the
experiment, showed a significant increase in the amount of IL-10
per cell compared to control mice, measured as mean fluorescence
intensity (MFI), though there was no difference in the number of
IL-10-producing cells (data not shown). Gating on different cell
populations demonstrated that IL-10 was in particular produced
by B cells, and by non-B antigen presenting cells (APC) (Figure 2
B, C and 2F). The proportion and expression (MFI) of IL-10 in B
cells and non-B cell APCs in spleen were similar between the
groups (Figure 2 D–E). Analysing IL-10 in serum by ELISA
showed similar levels in both groups of mice (data not shown).
Taken together this suggests that IL-10 acts locally in the lymph
nodes rather than on a systemic level.
To investigate the link between increased IL-10 production and
suppression of arthritis we determined the mRNA levels of the
suppressors of cytokine signalling 1 and 3 (SOCS1 and SOCS3).
The SOCS proteins are key negative regulators of cytokine
responses and act via inhibition of the intracellular JAK/STAT
signalling pathways [14], and IL-10 has previously been shown to
induce these adaptor proteins [15]. We found elevated mRNA
levels of SOCS1 and the same tendency (p = 0.12) also for SOCS3
in peripheral lymph nodes in LNT-IL-10 mice (Figure 2G). These
data show that a local increase in IL-10 results in an increase in
SOCS expression which correlates with suppression of arthritis
development.
LNT-IL-10 Influences Serum Protein Levels of Cytokines
and Anti-CII Antibodies
The effect by IL-10 may be direct or indirect and we were,
therefore, interested in potential effects on other cytokines. Indeed,
we found a significant decrease in serum levels of IL-6 in LNT-IL-
10 mice at day 29 after CII immunisation (Figure 3A). At day 42,
although the levels were still very low in LNT-IL-10 mice, the
levels of IL-6 in control mice had declined and the difference
between the groups were no longer significant. Serum levels of
a number of additional cytokines (IL-1a, IL-2, IL-4, IL-5, IL-10,
IL-13, IL-17A, IL-21, IL-27, IFN-c) were measured without any
significant differences between the groups (data not shown).
Previous work have shown that IL-6 promotes the development of
arthritis as it together with TGF-b induces Th17 cells and
stimulates B cells to increased production of IgG and IgA
antibodies [16]. As may be expected, based on its effect on
antibody producing cells, the serum levels of anti-CII specific IgG
antibodies were decreased in LNT-IL-10 mice compared with
LNT-GFP controls at days 42 and 49 (Figure 3B). These data
demonstrate that an increase in local IL-10 expression in lymph
nodes, but not in spleen, in LNT-IL-10 animals is accompanied by
reduced serum levels of IL-6 and anti-CII antibodies. These
findings indicate that local IL-10 production in the draining lymph
nodes of arthritic joints acts via induction of an anti-inflammatory
response that influences systemic cytokine levels and autoantibody
production by B cells.
LNT-IL-10 Influences Sizes of Cell Populations in Both
Lymph Nodes and Spleen
IL-10 and IL-6 are potent inhibitors as well as activators of cell
proliferation and differentiation. Because our data showed
alterations in the levels of these cytokines between the groups we
sought to determine whether this was associated with any
differences in the proportions of B and T cells. Late during the
course of arthritis (day 42) the proportion of CD19+ MHCII+ B
cells was decreased in lymph nodes in LNT-IL-10 mice whereas
the proportion of CD4+ Foxp3+ regulatory T cells was not affected
(Figure 4A and D). At this late time point CIA has become
a systemic disease and cell populations in spleen were also
determined. In LNT-IL-10 mice the proportion of CD19+
MHCII+ B cells was decreased, and that of CD4+ Foxp3+
regulatory T cells increased (Figure 4B and D). However, in actual
cell numbers this corresponded to an absolute decrease in B cells,
but similar numbers of CD4+ Foxp3+ regulatory T cells as in
controls (Figure 4C). Thus, the main effect of LNT-IL-10 appears
to be on the B cell compartment.
Disease-Dependent IL-10 Ameliorates CIA
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Figure 1. Lentiviral gene constructs and clinical development of arthritis. (A) Lentiviral constructs: LNT-GFP and LNT-IL-10. LTR; long
terminal repeat, cPPT; central polypurine tract, pA; polyadenylic acid tail, WPRE; Woodchuck post-transcriptional regulatory element, IL-1E;
Interleukin-1 enhancer, IL-6 promoter. (B) Severity of arthritis (mean arthritis score6 SEM). LNT-GFP (day 0–42 n= 18, day 44–49 n= 10) and LNT-IL-10
(day 0–42 n= 25, day 44–49 n= 14)). (C) Histopathological severity of synovitis and cartilage and bone erosivity measured as histological severity
score (Y-axis) ranging from 0–3. Data in figure 1B and C were analysed by Mann-Whitney U-test. Closed circles represents LNT-GFP and open circles
LNT-IL-10 mice. Bars in 1C represent the median.
doi:10.1371/journal.pone.0049731.g001
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Discussion
Our report shows that increased local, but not systemic, levels of
IL-10 conferred by disease-driven gene therapy delays the
progression of CIA in mice. A precise and restricted increase in
IL-10, produced by B cells and other APCs, ameliorates the course
and severity of arthritis. Based on our data, a possible scenario
would be that the increase in IL-10 upregulates SOCS1 resulting
in a decrease in serum levels of IL-6. This in turn results in
a decrease in both frequency and number of B cells and anti-CII
antibody levels, accompanied by reduced severity of arthritis.
IL-10 is a potent pleiotropic cytokine that is produced e.g. by
monocytes, macrophages, T and B cells. This cytokine has the
capacity to inhibit synthesis of pro-inflammatory cytokines such as
IL-2, IFN-c, TNF-a and importantly IL-6 [4]. It has earlier been
shown that systemically increased IL-10 levels suppresses the
frequency and severity of CIA [17,18,19,20,21]. The inflamma-
tion-dependent IL-1/IL-6 promoter has low basal activity, which
significantly increases during acute inflammatory conditions [13].
We found that this promoter, driving the IL-10 gene expression,
does not induce increased systemic (serum) levels of IL-10 during
the course of arthritis in vivo, but a locally increased IL-10
expression in lymph nodes; particularly in B cells and other APCs.
Whether the B cells in the LNT-IL-10 mice are IL-10- producing
regulatory B cells [17] is currently unknown, although it is possible
as such cells have been found to reduce the severity of arthritis
[18,22]. Our data are supported by those of others [12], where it
was recently found that a local and inflammation-dependent
increase in IL-10 produced by endothelial cells results in
suppressed development of zymosan induced arthritis in mice.
Interleukin-6 has been found to contribute to the development
of synovitis as well as cartilage and bone destruction in
autoimmune arthritis (reviewed in [23]). As expected, IL-6 was
almost absent in the LNT-IL-10 mice but not in the arthritic
control group. IL-6 is regulated by a multitude of mechanisms
including SOCS1 and 3 e.g. SOCS1 down regulates its expression
[24]. The SOCS adaptor proteins are in turn induced by IL-10
[15]. In fact, increased expression of both SOCS1 and 3 have been
shown to decrease the severity of arthritis [15,25,26]. In our
system, increased production of IL-10 in lymph nodes coincides
with elevated mRNA levels of SOCS1 and decreased levels of IL-
6. It is also known that IL-6 in the presence of TGF-b drives
ROR-ct expression in naı¨ve T cells to Th17 cells, while the
absence of IL-6 induces FoxP3 expression and expansion of T
Figure 2. Levels of IL-10 mRNA, intracellular IL-10 production and SOCS expression (A). Levels of IL-10 mRNA expression in lymph nodes
at day 42 in LNT-GFP or LNT-IL-10 mice. (B) The amount of IL-10/cell measured as geometric mean flourescent intensity (MFI) in lymph node
CD19+MHC II+B cells, (C) in lymph node CD19-MHC II+non-B APCs (D) in splenic B cells, (E) in splenic non-B APCs. (F) Typical gating for intracellular
cytokine staining showing one sample from an LNT-GFP mouse and an LNT-IL-10 mouse (G) Levels of mRNA SOCS1 and 3 expression in draining
lymph nodes at day 42. In figure 2A–E and G data were analysed by Mann-Whitney U-test. Closed circles represents LNT-GFP and open circles LNT-IL-
10 mice.
doi:10.1371/journal.pone.0049731.g002
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regulatory cells [27,28,29]. At the studied time points, no
differences in the number of T regulatory cells or serum levels of
IL-17 could be detected, suggesting that this mechanism is less
likely.
The frequency of B cells is decreased both locally in lymph
nodes and systemically in spleen of LNT-IL-10 mice compared
with controls. This effect might be attributed mainly to decreased
IL-6 levels as the cytokine originally was identified as a B-cell
differentiation factor and plays an important role in the de-
velopment of antibody-producing plasma cells [30]. Beside the fact
that fewer B cells can lead to lower levels of anti-CII IgG
antibodies (which also could be due to a less inflammatory status),
the beneficial effects of a reduced B cell population is well
described in the outcome of human RA by the use of B cell
depleting anti-CD20 antibodies [31].
Our study suggests that inflammation-dependent IL-10 pro-
duction causing locally increased levels of IL-10, increased SOCS1
mRNA and a decrease in systemic IL-6 levels ameliorate the
outcome of CIA in mice. However, the concept needs to be tested
in human RA, as the role of IL-10 in RA patients is far from
clarified: RA patients have significantly elevated levels of IL-10 in
synovial fluid [32] while the expression of IL-10 receptors are
reduced in synovial tissue [33] compared with osteoarthritic
controls, and treatment with systemic recombinant IL-10 in
human RA patients has so far not shown any convincing results
[34]. Although these findings appear disappointing they do not
contradict our data. Rather, they suggest that the anti-arthrito-
genic effect might be dependent on a requirement for localised
rather than systemic IL-10 treatment.
Taken together, our study demonstrates that disease-regulat-
ed therapy mediated by IL-10 has a beneficial outcome on arthritis
development in CIA and provides a step towards disease-regulated
therapies in human autoimmune arthritis.
Materials and Methods
Cloning of Inflammation Dependent GFP and IL-10
Lentiviral Vectors
To generate the inflammation dependent lentiviral vector
encoding the green flourescent protein (GFP), pGL3B containing
the hybrid promoter (IL-1/IL-6) was digested with BglII/Hind1I1.
The 1.3 kilo base pair (kbp) fragment was subcloned into
a modified pBluescript vector, to have additional cloning sites,
Pac1/Asc1. By using Pac1/Asc1 the promoter fragment was further
subcloned into pHR’SIN-cPPT-SEW containing both GFP and
woodchuck post-transcriptional regulatory element (WPRE). The
vector was named LNT-GFP. To create the inflammation
dependent lentiviral encoding IL-10, the eGFP gene was digested
from the LNT-GFP by Pme1/Sal1. A pCI vector containing the IL-
10 cDNA was digested with Not1/Xho1 and replaced the eGFP
gene, creating the LNT-IL-10. All restriction enzymes and ligases
were obtained from New England Biolabs (NEB Ipswich, MA,
USA).
Production of Lentiviral Particles
Vesicular stomatitis virus-G (VSV-G) pseudotyped lentivirus
was produced by transient transfection of 293FT cells with three
plasmids: one of the self inactivating transfer vector plasmids
(LNT-GFP and LNT-IL-10); the multi-deleted packaging plasmid
pCMVDR8.74; and the VSV-G envelope pMD.G2 using calcium
phosphate co-precipitation. At 72 h post transfection, the medium
was harvested and concentrated by ultracentrifugation at
90,000 g. The pellets were resuspended in PBS containing 2%
FCS and stored at 280uC.
Lentiviral Particle Titration
Viral titer was determined on NIH/3T3 (American Type
Culture Collection, Manassas, VA, USA) mouse fibroblast cell line
using real time-PCR directed towards the WPRE sequence.
Vector copy numbers are normalised to titin gene copies. WPRE
forward primer: 59 GGC ACT GAC AAT TCC GTG GT 39,
WPRE reverse primer: 59 AGG GAC GTA GCA GAA GGA CG
39 and WPRE probe 59 6-FAM- ACG TCC TTT CCA TGG
CTG CTC GC- TAMRA- 39. Titin forward primer: 59 AAA
ACG AGC AGT GAC GTG AGC 39, titin reverse: 59 TTC AGT
CAT GCT GCT AGC GC 39 and titin probe: 59-6 FAM- TGC
ACG GAA GCG TCT CGT CTC AGT C- TAMRA- 39. All
primers were obtained from Sigma-Aldrich AB (St Louis, MO,
USA) and probes from Applied Biosystems and the assay was run
Figure 3. Levels of IL-6 and anti-CII antibodies (A) Serum protein
levels of IL-6 (B) and serum levels of anti-CII IgG were analysed at days
29 and 42 after CII immunisation. Analysed by Mann-Whitney U-test.
Closed circles represents LNT-GFP and open circles LNT-IL-10 mice.
doi:10.1371/journal.pone.0049731.g003
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with TaqmanH Universal PCR Mastermix (Applied Biosystems,
California, USA) on 7500 Real Time PCR System (Applied
Biosystems).
Mice
Male DBA/1 mice were obtained from Taconic (Europe A/S,
Ry, Denmark) and housed in a pathogen-free barrier facility (12-hr
light/12-hr dark cycle) and fed rodent chow. All animal studies
were approved by the local Animal Ethics Committee.
Inflammation-dependent Production of IL-10 in vitro
To verify inflammation-dependent IL-10 production, bone
marrow was harvested from femur and the hip bone from
DBA/1 mice and HSCs were isolated with negative selection using
EasySepH Mouse Hematopoietic Progenitor Cell Enrichment Kit
(Stemcell Technologies, Manchester, UK). After isolation, HSCs
were resuspended in StemSpan with 1% penicillin/streptomycin
and the following cytokines (100 ng/ml mSCF, 100 ng/ml Flt-3L,
100 ng/ml IL-11, 20 ng/ml IL-3) and cultured in 12 well plates at
a concentration of 1 6 106 cells/ml. The cells were transduced
with lentiviral constructs LNT-GFP and LNT-IL-10 at MOI
ranging from 0 to 80. The next day the media was changed to
a media promoting differentiation of haematopoetic cells to bone
marrow derived macrophages containing DMEM supplemented
with 10% FCS, 10% L929- conditioned media, 20 mM HEPES
and 50 mM 2-mercaptoethanol. After 9 days of differentiation the
cells were stimulated with 100 ng/ml LipoPolySaccharide (LPS) or
media for 24 h. Supernatants were collected and analysed by
mouse Duoset IL-10 ELISA (R&D Systems, Abingdon, UK)
according to the manufacturers instructions.
Bone Marrow Transplantation
To minimize risk for infections during transplantation, both
donor and recipient mice were treated with the antibiotic
(enrofloxacin) BaytrilH one week prior to and two weeks after
the transplantation. Haematopoetic stem cells were harvested,
isolated from donor mice as described in the paragraph above and
further transduced with lentiviral constructs LNT-GFP and LNT-
IL-10 at MOI 75 and incubated at 37uC overnight. The next
morning, cells were washed with PBS twice, counted and
resuspended at a concentration of 2.4 6 105 cells/200 ml. The
recipient mice were irradiated with 8.5 Gy and intravenously
reconstituted with transduced HSCs (2.4 6 105). Mice were
repopulated for 12 weeks before induction of arthritis.
Assessment of in vivo Transgene Integration by PCR
To detect vector integration in bone marrow, spleen and
synovium 18 weeks after transplantation of transduced HSCs,
DNA was prepared using the QIAamp DNA mini kit (Qiagen,
Solna, Sweden) according to the manufacturer’s instructions and
the WPRE was amplified with primers and probes described
above.
Collagen Type II Induced Arthritis
Two independent experiments were performed and the data
were pooled. Arthritis was induced 12 weeks after bone marrow
transplantation by a subcutaneous (sc) injection of chicken CII
(Sigma-Aldrich AB) (1 mg/ml) in complete freund’s adjuvant
(Sigma-Aldrich AB) in a total volume of 100 ml. The mice were
boosted sc with CII (1 mg/ml, 100 mg/mouse) in incomplete
Figure 4. T and B cell populations in lymph nodes and spleen after CII immunisation. (A) Percentages of CD19+MHCII+ cells and
CD4+FoxP3+ cells in lymph node, (B) and in spleen (C) Absolute numbers of CD19+MHCII+ cells and CD4+FoxP3+ cells in spleen. (D) Typical gating for
isotype control and Foxp3 antibody in CD4+T cells from a LNT-GFP and a LNT-IL-10 mouse. All data were analysed by MannWhitney U-test. Closed
circles represents LNT-GFP and open circles LNT-IL-10 mice.
doi:10.1371/journal.pone.0049731.g004
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freund’s adjuvant (Sigma-Aldrich AB) at day 21 after CII
immunisation. All mice were followed individually and checked
daily. Clinical arthritis and severity was assessed by an evaluator
blinded to the treatment groups. Finger/toe and ankle/wrist joints
were inspected and arthritis was defined as visible erythema and or
swelling. To evaluate the severity of arthritis, a clinical scoring
(arthritic index) was carried out using a system where macroscopic
inspection yielded a score of 0–3 points for each limb. We define
our scoring system as follows: 0– no arthritis, 1– mild arthritis
(mild swelling and a subtle erythema of the evaluated joint), 2–
moderate arthritis (moderate swelling and a more pronounced
erythema compared to score 1), 3– severe arthritis (profound
swelling and erythema). The total score per animal and time point
is calculated by adding up the scores from all four paws. The mice
were bled at day 29. At day 42 blood, joints, spleen and lymph
nodes were obtained. Histopathologic examination of the joints
was performed after routine fixation, decalcification, and paraffin
embedding. Tissue sections from fore and hind paws were cut and
stained with hematoxylin–eosin. All the slides were coded and
evaluated by two blinded observers. The specimens were
evaluated with regard to synovial hypertrophy, pannus formation,
and cartilage/subchondral bone destruction. The degree of
synovitis and destruction in every joint concerning finger/toes,
wrists/ankles, elbows, and knees was assigned a score from 0 to 3.
Occasionally one paw was missing in the histological sections, or
embedded in such a way that it was impossible to evaluate the
degree of synovitis and bone/cartilage destruction. Therefore, the
total score per mouse was divided by the number of joints
evaluated.
Determination of mRNA Levels of IL-10 in Lymph Nodes
RNA was isolated from lymph nodes using RNEasy mini kit
(Qiagen). The RNA quality was analysed using a Experion
Bioanalyzer on a Experion RNA StdSens chip (Bio-Rad labora-
tories Inc., USA) prior to cDNA synthesis with High Capacity
cDNA Reverse Transcription kit (Applied Biosystems). The
expression of IL-10 gene was analysed using primers IL10 FW
59-CATTTGAATTCCCTGGGTGAGA and RV 59-
TGCTCCACTGCCTTGCTCTT. The gene expression was
normalised to b-actin analysed with primers FW 59-CTGACAG-
GATGCAGAAGGAGATTACT and RV 59-GCCACCGATC-
CACACAGAGT. The reactions were amplified using Power
SYBR green PCR Master Mix (Applied Biosystems) and analysed
on a Viia7 system (Applied Biosystems).
Fluorescence Activated Cell Sorting (FACS) Analyses and
Cell Counting
To detect intracellular cytokine expression in different cell
populations, a single cell preparation of lymph node and spleen
was performed. The total number of cells in spleen was counted
(Nucleocounter, ChemoMetec AS, Denmark). For FACS stain-
ings, 16106 from lymph nodes or spleen were placed in 96-well
plates and pelleted (3 min, 300 g, 4uC). To avoid nonspecific
binding via Fc-receptor interactions, cells were incubated with Fc-
block (2.4G2, BD Biosciences, San Jose, CA, USA) for 10 min at
room temperature. Antibodies used were anti-CD19 (clone ID3),
anti-CD4 (clone RM4-5), anti-IL-10 (clone JES5-16E3) and anti-
IFN-c (clone XMG1.2) purchased from BD Biosciences, anti I-A/
I-E (clone M5/114.15.2 purchased from BioLegend, San Diego,
CA, USA) and FoxP3 (clone FJK-16s), and IL-17 (clone
eBio17B7), purchased from eBioscience (San Jose´, CA, USA).
All surface marker antibodies were diluted in FACS-buffer (PBS
containing, 1% FCS and 0.5 mM EDTA). For intracellular
staining with anti-IL-10 or isotype controls the cells were
permeabilised using the FoxP3/Transcription Factor Staining
Buffer set from eBiosciences and antibodies diluted in 16PERM
buffer included in the kit. The antibodies were directly conjugated
with fluorescein isothiocyanate (FITC), phycoerythin (PE), allo-
phycocyanin (APC), V450 and APC-H7. Cells were stained as
previously described and gating of cells was performed using
fluorochrome minus one settings [35] and detected by FACS-
Canto IITM (BD Biosciences). Gating strategy for expression of IL-
10 was included in Supplemental Figure 2. Analysis with respect to
the number of cells and mean flourescence intensity (geometric
mean) were performed using FlowJo Software, Tree Star Inc.
(Ashland, OR, USA).
Determination of SOCS Expression in Lymph Nodes
RNA was isolated from lymph nodes using RNEasy mini kit
(QIAGEN). The RNA quality was analysed using a Experion
Bioanalyzer on a Experion RNA StdSens chip (BioRad) prior to
cDNA synthesis with High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). The gene expression of SOCS3 was
analysed using primers FW 59-CTGGTACTGAGCC-
GACCTCTCT-39 and RV 59-CCGTTGACAGTCTTCCGA-
CAA-39, the expression of SOCS1 was analysed using primers
SOCS1 FW 59-AAGGAACTCAGGTAGTCACGGAGTA-39
RV 59-CCGTGGGTCGCGAGAAC-39. The gene expression
was normalised to b-actin analysed with primers FW 59-
CTGACAGGATGCAGAAGGAGATTACT and RV 59-
GCCACCGATCCACACAGAGT. All reactions were amplified
using Power SYBR green PCR Master Mix (Applied Biosystems)
and analysed on a Viia7 system (Applied Biosystems).
Determination of Cytokine Production
Blood was centrifuged at 7000 g for 10 min. Serum was
collected and stored at 220uC for further analysis. Previously
prepared spleen cell culture were stimulated for 72 hours with
denatured chicken CII 50 mg/ml, supernatants collected and kept
in 220uC until further analysed. Two independent experiments
were performed. In the first experiment serum protein levels of IL-
10 were measured in serum by Duoset ELISA (R&D systems)
according to the manufacturer’s recommendations and detected
on Spectra Max 340PC (Molecular Devices). In the second
experiment serum levels of Th1, Th2, Th17 and Th22 specific
cytokines (IL-1a, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-
21, IL-22, IL-27 and IFN-c) were measured using FlowCytomix
Multiple Analyte Detection Mouse Th1/Th2/Th17/Th22 13plex
Kit (eBioscience). The assay was run on FACSCanto IITM (BD
Biosciences). Analyses were performed using FlowJo Software,
Tree Star Inc. (Ashland, OR, USA).
Determination of the Anti-CII-specific IgG Antibodies
For quantification of anti-CII antibodies in serum, 96-well
plates (Nunc, Roskilde, Denmark) were coated overnight at 4uC
with 10 mg/ml of native chicken CII (Sigma-Aldrich AB). The
samples were serially diluted (1:250, 1:750, 1:2250, 1:6750) in
0.5% bovine serum albumin (BSA) (Sigma-Aldrich AB) in PBS.
Biotinylated F(abN)2 fragments of goat anti-mouse IgG (Jackson
Immuno Research Laboratories, Suffolk, England) were used as
secondary antibody. Development was performed using horserad-
ish peroxidase 0.5 mg/ml and 2.5 mg of the enzyme substrate 2,2-
azino-bis-(3-ethylbenzothiazoline sulfonic acid) (Sigma-Aldrich
AB) per ml in citrate buffer (pH 4.2), containing 0.0075%
H2O2. The absorbance was measured at 405 nm on Spectra
Max 340PC (Molecular Devices, Sunnyvale, CA, USA).
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Statistical Analysis
The levels of IL-10 in supernatants after treatment with LNT-
GFP or LNT-IL-10 before and after LPS stimulation were
compared using Two-way ANOVA (GraphPad Prism, GraphPad
software, San Diego, CA, USA). All other statistical analysis
between independent groups were calculated using the non-
parametric Mann-Whitney U-test (GraphPad Prism) as described
in the figure legends. A P-value #0.05 was regarded as being
statistically significant.
Supporting Information
Figure S1 Integration of lentiviral vector and IL-10
production in vitro. (A) The protein level of IL-10 in
supernatants 9 days after in vitro transduction of HSCs with
LNT-GFP or LNT-IL-10 at MOI 0, 40 or 80 and with or without
LPS stimulation. (B) Integration of lentiviral vectors in bone
marrow, spleen and synovial cells. The number of lentiviral
particles LNT-GFP or LNT-IL-10 are expressed per 100 bone
marrow cells, splenocytes or synovial cells. Data in figure 1A were
analysed by Two-way ANOVA and data in figure 1B were
analysed by Mann-Whitney U-test. Closed circles and black bars
represents LNT-GFP and open circles and white bars LNT-IL-10
mice.
(TIFF)
Figure S2 Gating strategy for detecting IL-10 expression
in CD19+MHCII+ B cells using flow cytometry.
(TIFF)
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